Indeed, reports of reduction in circulating IL-4, IL-6, and IL-10 levels post-cancer treatment with chemotherapy in breast cancer patients12 proposed that tumour regression has the potential to attenuate the activity of the immune system, which could explain the reduction in coronary inflammation observed here after cancer treatment with RT. This evidence concerns the gene IL6 and breast cancer.